Relevant bibliographies by topics / Cardiovascular outcome

Academic literature on the topic 'Cardiovascular outcome'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cardiovascular outcome.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cardiovascular outcome"

1

Scheen, A. J. "Sibutramine on Cardiovascular Outcome." Diabetes Care 34, Supplement_2 (April 27, 2011): S114—S119. http://dx.doi.org/10.2337/dc11-s205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Voilliot, Damien, Julien Magne, Raluca Dulgheru, Seisyou Kou, Christine Henri, Luis Caballero, Carla De Sousa, et al. "Cardiovascular outcome in systemic sclerosis." Acta Cardiologica 70, no. 5 (October 2015): 554–63. http://dx.doi.org/10.1080/ac.70.5.3110516.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zoungas, Sophia, and Roland P. Asmar. "ARTERIAL STIFFNESS AND CARDIOVASCULAR OUTCOME." Clinical and Experimental Pharmacology and Physiology 34, no. 7 (July 2007): 647–51. http://dx.doi.org/10.1111/j.1440-1681.2007.04654.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ye, Yuanzi, and Ricardo Fonseca. "Overestimation of cardiovascular outcome incidence." Lancet 390, no. 10112 (December 2017): 2546–47. http://dx.doi.org/10.1016/s0140-6736(17)33084-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

McKay, Rachel Eshima. "Nitrous Oxide and Cardiovascular Outcome." Anesthesia & Analgesia 116, no. 5 (May 2013): 962–65. http://dx.doi.org/10.1213/ane.0b013e3182870e46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hansen, M. Rix, A. Pottegård, A. Hróbjartsson, P. Damkier, R. dePont Christensen, M. Olesen, and J. Hallas. "Modelling of Outcome Postponement for Cardiovascular Outcomes in Statin Trials." Clinical Therapeutics 39, no. 8 (August 2017): e11. http://dx.doi.org/10.1016/j.clinthera.2017.05.036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Seufert, Jochen, and Katharina Laubner. "Neue Antidiabetika und kardiovaskuläre Outcome-Studien." Diabetologie und Stoffwechsel 12, no. 04 (August 2017): 273–85. http://dx.doi.org/10.1055/s-0042-121159.

Full text
Abstract:
AbstractType 2 diabetes mellitus (T2DM) represents a major risk factor for the development of cardiovascular events, and cardiovascular mortality determines overall mortality in these patients. So far, glucose lowering per se has demonstrated a small effect in reduction of cardiovascular risk in T2DM patients. Due to regulatory purposes, since 2008 all novel antidiabetic medications, such as DPP4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors are investigated in dedicated cardiovascular outcome trials to demonstrate cardiovascular safety (non-inferiority trials). While the currently completed cardiovascular outcome trials for the DPP4 inhibitors sitagliptin, saxagliptin and alogliptin consistently demonstrated a neutral effect on cardiovascular risk, those trials for the GLP-1 receptor agonists revealed differential outcomes. Lixisenatide effects were neutral on cardiovascular outcomes while Liraglutide and Semaglutide demonstrated a reduction in cardiovascular risk. Most impressively was cardiovascular mortality, overall mortality and hospitalisation for heart failure reduced by the SGLT2 inhibitor empagliflozin in its dedicated outcome trial. These results strongly imply that certain novel antihyperglycaemic agents bear the potential to strongly reduce cardiovascular risk in patients with T2DM beyond their glucose lowering potency. The potential to reduce cardiovascular risk in patients with T2DM will selectively determine the clinical application of antidiabetic medications in the future.
APA, Harvard, Vancouver, ISO, and other styles
8

Langslet, Gisle, Bernard Zinman, Christoph Wanner, Stefan Hantel, Rosa-Maria Espadero, David Fitchett, and Odd Erik Johansen. "Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®." Diabetes and Vascular Disease Research 17, no. 6 (November 2020): 147916412097525. http://dx.doi.org/10.1177/1479164120975256.

Full text
Abstract:
Objective: It is well established that higher low-density lipoprotein (LDL)-cholesterol levels are associated with increased cardiovascular risk. We analyzed whether effects of empagliflozin on cardiovascular outcomes varied by different LDL-cholesterol levels at baseline in EMPA-REG OUTCOME. Methods: Participants with type 2 diabetes and high cardiovascular risk received empagliflozin (10/25 mg) or placebo in addition to standard of care. We investigated the time to first 3P-MACE, cardiovascular death, hospitalization for heart failure (HHF) and all-cause mortality for empagliflozin versus placebo between baseline LDL-cholesterol categories <1.8, 1.8–<2.2, 2.2– <2.6, 2.6–3.0, and > 3.0 mmol/L, by a Cox regression including the interaction of baseline LDL-cholesterol category and treatment. Results: Of the 7020 participants randomized and treated, 81.0% received lipid lowering therapy (77.0% statins). Mean ± SD LDL-cholesterol was 2.2 ± 0.9 mmol/L, and 38%/18%, had LDL-cholesterol <1.8/>3.0 mmol/L. Age, BMI, and HbA1c levels were balanced between the LDL-cholesterol subgroups, but those in the lowest versus highest group, had more coronary artery disease (83.0% vs 59.9%) and statin treatment (88.2% vs 50.9%). Empagliflozin consistently reduced all outcomes across LDL-cholesterol categories (all interaction p-values > 0.05). Conclusion: The beneficial cardiovascular effects of empagliflozin was consistent across higher and lower LDL-cholesterol levels at baseline.
APA, Harvard, Vancouver, ISO, and other styles
9

Fisher, Miles. "Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME." British Journal of Diabetes 20, no. 2 (December 13, 2020): 138–41. http://dx.doi.org/10.15277/bjd.2020.254.

Full text
Abstract:
EMPA-REG OUTCOME was an FDA-mandated cardiovascular outcome trial with empagliflozin and was the first completed trial with a sodium-glucose co-transporter-2 (SGLT2) inhibitor. EMPA-REG OUTCOME compared empagliflozin and placebo in 7,020 subjects with type 2 diabetes and established atherosclerotic cardiovascular disease. The results were astounding as EMPA-REG OUTCOME demonstrated superiority for major cardiovascular events (cardiovascular death, myocardial infarction, stroke) and cardiovascular deaths were significantly reduced, as was all-cause mortality. Hospitalisation for heart failure, which was a secondary outcome, was also significantly reduced. Later trials with SGLT2 inhibitors have demonstrated reductions in major adverse cardiovascular events (MACE) and hospitalisation for heart failure, and trials with glucagon-like peptide 1 receptor agonists have demonstrated reductions in MACE. Collectively, these trials could transform the management of people with type 2 diabetes.
APA, Harvard, Vancouver, ISO, and other styles
10

Bayliss, Elizabeth A., Liza M. Reifler, Chan Zeng, Deanna B. McQuillan, Jennifer L. Ellis, and John F. Steiner. "Competing Risks of Cancer Mortality and Cardiovascular Events in Individuals with Multimorbidity." Journal of Comorbidity 4, no. 1 (January 2014): 29–36. http://dx.doi.org/10.15256/joc.2014.4.41.

Full text
Abstract:
Background Cancer patients with cardiovascular and other comorbidities are at concurrent risk of multiple adverse outcomes. However, most treatment decisions are guided by evidence from single-outcome models, which may be misleading for multimorbid patients. Objective We assessed the interacting effects of cancer, cardiovascular, and other morbidity burdens on the competing outcomes of cancer mortality, serious cardiovascular events, and other-cause mortality. Design We analyzed a cohort of 6,500 adults with initial cancer diagnosis between 2001 and 2008, SEER 5-year survival ≥26%, and a range of cardiovascular risk factors. We estimated the cumulative incidence of cancer mortality, a serious cardiovascular event (myocardial infarction, coronary revascularization, or cardiovascular mortality), and other-cause mortality over 5 years, and identified factors associated with the competing risks of each outcome using cause-specific Cox proportional hazard models. Results Following cancer diagnosis, there were 996 (15.3%) cancer deaths, 328 (5.1%) serious cardiovascular events, and 542 (8.3%) deaths from other causes. In all, 4,634 (71.3%) cohort members had none of these outcomes. Although cancer prognosis had the greatest effect, cardiovascular and other morbidity also independently increased the hazard of each outcome. The effect of cancer prognosis on outcome was greatest in year 1, and the effect of other morbidity was greater in individuals with better cancer prognoses. Conclusion In multimorbid oncology populations, comorbidities interact to affect the competing risk of different outcomes. Quantifying these risks may provide persons with cancer plus cardiovascular and other comorbidities more accurate information for shared decision-making than risks calculated from single-outcome models.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cardiovascular outcome"

1

Daragjati, Julia. "Gender differences in therapies and outcome in cardiovascular disease." Doctoral thesis, Università degli studi di Padova, 2014. http://hdl.handle.net/11577/3424552.

Full text
Abstract:
The purpose of this analysis was to explore, by using an administrative database, gender and age differences in drug prescriptions of ordinarily residents, entitled to either free or subsidised approved prescribed drugs and medicines and and surgical interventions provided from the Local Health Service. Further analysis was performed in the cohort of patients that experienced an ACS during 2008. Methods: All residents of the Local Health Service Area 16 of the Veneto Region (Italy) ages 15-44, 45-64, 65-79 and >=80 years in the period 1st of January until 31st of December 2010, were included in the study. The Local Health Service system, covering this area, keeps record of all drug prescriptions dispensed by public or private pharmacies. All medications dispensed during 2010 were considered and classified according to Anatomical Therapeutic Chemical (ATC) classification system. Results were reported as odds ratios (OR) of prescriptions dispensed to males and females with 95% confidence intervals (CI) to analyse the number of subjects that received at least one medication. A detailed analysis was conducted for Cardiovascular drugs (ATC: C) in the cohort of 1,204 ACS patients (760 men and 444 women) being admitted in Saint’Anthony Hospital. Data of therapies and interventions were collected from the hospital and local medical distribution database. Results: Of the 491,261 included subjects, 255,026 were females and 236,235 males. Females were medicine dispensed in most of ATC subgroups as with antiulcer drugs (OR=0.80, 95% confidence interval [CI] 0.74-0.86), antibiotics(39% M vs. 46% F, p<0.001) as for tetracyclines (OR=0.91 95% CI 0.85-0.93), penicillins (OR=0.90 in the 95% CI 0.83-0.94), antimigraine preparations (OR 0.34 95% CI 0.0.31-0.36), antipsychotics (OR=0.86, 95% CI 0.81-0.90), antidepressants (3.74%M vs. 8.09% F, OR=0.44, 95% CI 0.40-0.52) diuretics (OR=0.72, 95% CI 0.66-0.80). On the other hand, males were dispensed more with antidiabetic drugs, insulin therapy (OR= 1.24 95% CI 1.21-1.30) and with oral hypoglycaemic (OR=1.37 95% CI 1.33-1.40), more exposed to treatment for cardiovascular disease with antithrombotic agents (12.11% M vs. 11.33%F, OR=1.16 95% CI 1.14-1.20), betablockers (OR=1.15 95% CI 1.10-1.20), ACE-inhibitors (OR=1.25 95% CI 1.20-1.30). Males were generally more prescribed with cardiovascular medications than their female counterparts. An obvious gender difference in drug utilisation was noticed during the 15-44 years of age, this difference decreased with aging, but still the medication use difference remained statistically significant. The prevalence of ACS was 2.5 ‰ (3.26‰ in male patients and 0.92‰ in female patients, OR=1.7 95% CI 1.4-2.0). Of the ACS patients, 142 (11.8%) died in hospital without any gender and age difference. Thus, for further investigations a cohort of 1,062 ACS patients (688 male and 374 female patients) was considered. Of these patients 40.12% underwent a revascularization intervention and 48.1% were not revascularised. Male patients over 65 years of age (73.4%) were significantly more likely to have a revascularization than the female patients (26.6%) of the same age (age group: 65-79, OR=1.7 95%CI 1.2-2.5; age group >=80, OR=4.1 95%CI 2.2-7.6). Six months after hospital discharge antiaggregation therapy was analysed. In the ACS population 82% received at least one antiaggregant. The remaining population 18% did not receive any antiaggregant at all, generally those were female patients (OR=2.8 95%CI 2.1-3.8). Aspirin was used in 35% of the non- revascularized vs. 28 % of the revascularized patient especially in non-revascularized female patients; Thienopyridines were dispensed in 8% of the non-revascularized vs. 5% of the revascularized patients especially in revascularized female patients, dual antiplateletes therapy was more dispensed in revascularized patients (61% vs. 29%), especially in male non-revascularized patients. For the other non mentioned therapies male and female patients were treated equally. Regarding to therapy adherence, male patients were in general more adherent to Aspirin (92%M vs. 82%F, OR=2.4 95%CI 1.2-4.6) on the other hand, to Thienopyridines (87%M vs. 84%F, OR=1.3 95%CI 0.3-5.0) and to Dual-antiplateletes therapy (76%M vs.74%F, OR=1.1 95%CI 0.7-1.8) both male and female patients were adherent without gender differences. Conclusions: As women are more exposed to chronic and acute conditions, especially in the reproductive years 15 to 44 and in pre- and post-menopausal age, according to the literature, our results support the suggestion that females are dispensed more medicines than males in general. On the contrary, men were more exposed to cardiovascular drugs than women. ACS occured more frequently in men than in women. In general men were more revascularized than women. On discharge, female patients were not usually treated with antiaggregant therapy, more often than their male counterparts. Revascularized patients compared to non-revascularized patients did not have any gender difference in terms of therapy, but an evaluation between non-revascularized patients indicated an inequity between male-female patients use of antiaggregants. On the whole, both female and male ACS patients were adherent to therapy. In general, men had a better survival than women
L’obbiettivo iniziale della ricerca è stato quello di descrivere la storia prescrittiva di tutti i farmaci nell’anno 2010. Tramite l’analisi dei dati di prescrizione provenienti dall’Assistenza Farmaceutica Territoriale di Padova è stato possibile descrivere l’utilizzo di questi farmaci nella popolazione generale. Sono risultati maggiormente utilizzati: gli antibiotici (con 39% M vs 46 % F con almeno un antibiotico prescritto, p<0,001), gli antiulcera( 13,20% M vs 16,68 % F, p<0,001), gli antireumatici (10,84% M vs 16,70 % F, p<0,001), gli antidepressivi (con 3,74% M vs 8,09 % F, p<0,001) etc., con una prevalenza di trattati del genere femminile. Una prevalenza di trattati del genere maschile è stata osservata invece per gli antitrombotici (con 12,11% M vs 11,33% F, p<0,025), gli antidiabetici di cui insulino-trattati 1,26% M vs 1,03 % F, p<0,05 ed i trattati con ipoglicemizzanti 3,73% M vs 2,83 % F, p<0,05) ed i dislipidemici (8,93%M vs 8,08%F, p<0,025) etc. Tutti questi dati riportati sono statisticamente significativi. Questa analisi indica anche che il genere femminile è in assoluto il maggior consumatore di farmaci antidolorifici, risultato che porta a dedurre che le donne soffrono maggiormente di dolore acuto e cronico, ma può essere anche un indicatore di una maggiore propensione della donna alla ricerca di una visita medica rispetto all’uomo, il quale forse preferisce rimedi autogestibili (OTC oppure a fumo e alcool). L’alto numero di donne fra i trattati con farmaci del sistema nervoso (antipsicotici, antidepressivi) fa pensare a questi “giorni moderni” in cui la donna è ancora vittima di violenza non solo fisica, ma anche psichica, e si trova spesso sottoposta a stress, come risultato dell’emancipazione. La moglie-madre-donna in carriera è esposta ad una vita frenetica e le tante responsabilità accumulate negli anni tendono a portarla alla parità col genere maschile. Una analisi più approfondita è stata fatta nello specifico per i farmaci cardiovascolari. La maggior parte dei farmaci cardiovascolari è stato dispensato prevalentemente al genere maschile, ma bisogna sottolineare che le malattie cardiovascolari erano la causa principale di morte in entrambi i sessi. Non si è verificata alcuna differenza di genere nella prevalenza di trattati per i sottogruppi dei betabloccanti non associati, calcio antagonisti con effetto cardio-diretto e antagonisti dell’angiotensina II, mentre per gli antitrombotici, gli antiaritmici di classe sia I che III, gli ipocolesterolemizzanti e ipotrigliceridemizzanti si è osservato un utilizzo maggiore nel genere maschile. Per quanto riguarda le malattie trombotiche, le femmine risultavano meno trattate dei maschi, in accordo con il fatto che il maschio adulto, a parità di età, è più propenso alla trombosi rispetto alla femmina adulta, perché con l’avanzare dell’età ha una maggiore aggregazione piastrinica rispetto alla femmina. Infine, l’attenzione è stata focalizzata sull’evento della sindrome coronarica acuta (SCA) per analizzare la presenza di eventuali differenze di genere in pazienti ospedalizzati per SCA in relazione ai seguenti indicatori: prevalenza di ricoveri per SCA, mortalità intra- ed extra-ospedaliera, tipologia di interventi di rivascolarizzazione, trattamento farmacologico alla dimissione, aderenza alla terapia e sopravivvenza. Nel corso dell’anno 2008, sono stati ricoverati per SCA 1.204 pazienti (760 maschi e 444 femmine). La prevalenza dei ricoveri è stata significativamente superiore negli uomini (3,26‰ ) rispetto alle donne (0,92‰) con OR = 1,7 (IC 95% = 1,4-2,0). Dei 1.204 pazienti arruolati 142, ovvero 11,8%, sono andati incontro a decesso intraospedaliero. Sono state analizzate le recidive a breve e lungo termine. Le donne in entrambi i casi andavano in contro a recidive più frequentemente degli uomini (nel 2009 il 17,9% delle donne vs. 12,6% degli uomini e nel 2012 32% donne vs. 24% degli uomini, p<0,05). Una fotografia della terapia nei 12 mesi precedenti l’evento evidenziava un trattamento con antiipertensivi e antidepressivi maggiore nelle donne. Per quanto riguarda il trattamento del diabete e delle dislipidemie non si evidenzia nessuna differenza di genere nell’utilizzo dei farmaci riguardanti queste patologie. E‘ stata fatta una analisi degli interventi di rivascolarizzazione per rilevare eventuali differenze di genere e differenze di età. Il 40,12% della popolazione è andata incontro a rivascolarizzazione invece il 48,1% non è stata rivascolarizzata. Nella fascia di età 65-79 anni il 73,4% dei maschi ha subito un intervento di rivascolarizzazione contro il 26,6% delle donne (OR=1,7 con IC 95% =1,2-2,5). Negli over 80, gli uomini sono sempre maggiormente rivascolarizzati (71,2%M vs 28,8F OR= 4,1 con IC 95% = 2,2-7,6). Questi dati hanno confermato che in generale gli uomini vengono sottoposti a questo tipo di interventi più delle donne. Per quanto riguarda l'aderenza alla terapia, i pazienti di sesso maschile sono stati più aderenti alla terapia limitatamente all’aspirina (92% M vs 82% F, OR = 2,4 IC 95% 1,2-4,6). L'analisi di sopravvivenza ha mostrato una prognosi migliore del genere maschile, con una mortalità più alta del genere femminile
APA, Harvard, Vancouver, ISO, and other styles
2

Mahendru, Amita. "A prospective study of implantation, maternal cardiovascular function and pregnancy outcome." Thesis, University of East Anglia, 2012. https://ueaeprints.uea.ac.uk/47385/.

Full text
Abstract:
Events at embryonic implantation play a key role in the establishment of successful pregnancy. Not only is delayed implantation associated with an increased incidence of early pregnancy loss, but may also be associated with impaired trophoblastic invasion and uteroplacental insufficiency. Furthermore, uteroplacental vascular mal-adaptation may also be affected by pre-existing maternal cardiovascular function and associated with maternal cardiovascular maladaptation during pregnancy. There is limited understanding of events surrounding human implantation because of the difficulties in conducting prospective studies from prior to pregnancy and an inability to study events at the trophoblast-decidual interface in vivo. The primary objective of this study was to test the feasibility of being able to conduct and complete a prospective study from prior to pregnancy to the postpartum period combining measures of ovulation, implantation, ultrasound measurements of fetal size and cardiovascular changes during pregnancy. The secondary objective was to investigate ovulation and implantation timing using digital home ovulation and pregnancy test kits along with cardiovascular changes in relation to various pregnancy complications and fetal growth to determine the power for a future prospective study. This was a prospective cohort feasibility study of 143 women planning to conceive. Pre-pregnancy cardiovascular function was investigated in all women. We observed ovulation, implantation timing in 101 pregnancies and investigated the relationship between implantation timing, embryonic and fetal growth, birthweight and length of gestation in the 69 viable pregnancies. Longitudinal cardiovascular changes in viable pregnancies were examined in relation both to previous obstetric history and index pregnancy outcome. Normal pregnancy was associated with profound cardiovascular changes, beginning from 6 weeks of gestation. Delayed implantation was associated with early pregnancy loss and a smaller first trimester fetal size. The incremental rise in cardiac output from before pregnancy to its peak in the second trimester was associated with birthweight. It is feasible to conduct and complete a prospective study from prior to pregnancy to the postpartum period. Larger prospective studies of this nature will enable an understanding of the events surrounding implantation including the ‘cause and effect’ relationship of cardiovascular function with pregnancy complications such as preeclampsia and fetal growth restriction.
APA, Harvard, Vancouver, ISO, and other styles
3

Cruz, Lemini Mónica Cristina. "Fetal cardiovascular dysfunction in intrauterine growth restriction as a predictive marker of perinatal outcome and cardiovascular disease in childhood." Doctoral thesis, Universitat de Barcelona, 2013. http://hdl.handle.net/10803/134221.

Full text
Abstract:
Most risk factors leading to cardiovascular disease are already present in childhood and the importance of early identification of pediatric cardiovascular risk factors is now well recognized. Hypertension in the child has been associated with substantial long-term health risks and considered an indication for lifestyle modifications. Current clinical guidelines contemplate screening for hypertension in children over 3 years of age, in order to provide strategies for promoting cardiovascular health, which can be integrated into comprehensive pediatric care. Interventions in the IUGR group could go from blood pressure monitoring before 3 years of age, recommending lack of exposure to other risk factors (secondary smoking, obesity), surveillance of catch-up growth or administration of hypotensors and specially, promoting exercise and physical activity. A recent randomized trial in a large cohort of children suggest that the inverse association of fetal growth with arterial wall thickness in childhood can be prevented by dietary ω-3 fatty acid supplementation over the first 5 years of life. IUGR is not listed among those conditions presumed to increase cardiovascular risk, in current guidelines. Considering IUGR affects 5-10% of all newborns, the findings of this study would affect thousands of children per year. Currently, there are no prenatal parameters described that may aid in selecting those fetuses with later hypertension and arterial remodeling that may benefit for early screening in infancy and other preventive measures or interventions. Both fetal and child cardiovascular evaluations have proven to be reliable techniques for describing changes in IUGR; cardiovascular dysfunction has been found subclinically and may have implications for cardiovascular risk in future life. The main aim of this work was to evaluate cardiovascular function parameters in IUGR fetuses as predictors of perinatal and postnatal cardiovascular outcome. In order to do this, we looked to validate the reproducibility of measurements and techniques not previously described in IUGR fetuses (studies 1 and 2), to evaluate whether fetal cardiovascular parameters could help us predict perinatal outcome (study 3) and finally to assess the value of fetal echocardiography for prediction of postnatal cardiovascular risk factors, specifically hypertension and arterial remodeling (study 4). This thesis confirms previous studies showing fetal cardiac dysfunction can be documented by fetal echocardiography; it validates different methods for evaluating cardiac function in the fetus and demonstrates the predictive value of these parameters for perinatal and postnatal cardiovascular outcome. Our first study demonstrates for the first time the validity of M-mode to assess longitudinal axis motion in IUGR. It further confirms previous research that IUGR fetuses have a significant decrease in longitudinal myocardial motion, as part of the fetal cardiovascular adaptation to placental insufficiency. In our second study, both TDI and 2D-derived strain analysis demonstrated to be feasible and reproducible to evaluate deformation parameters in the fetal heart. Our third study evaluated the independent and combined contribution of fetal cardiovascular parameters to the prediction of early-onset IUGR perinatal mortality. The study suggests an algorithm illustrating the chances of perinatal death against gestational age and DV, which might help clinical decisions in the management of early-onset IUGR fetuses. The fourth study provides, for the first time, evidence that fetal echocardiographic parameters are strongly associated to postnatal hypertension and arterial remodeling, which are recognized cardiovascular risk factors and surrogates for early-onset cardiovascular disease. It supports that a fetal cardiovascular score is strongly associated with the presence of postnatal hypertension and arterial remodeling at 6 months of age in IUGR. Echocardiographic parameters demonstrated a far better performance than perinatal factors and fetoplacental Doppler used for establishing the severity of IUGR.
Los fetos con restricción del crecimiento intrauterino (RCIU) presentan remodelamiento cardiovascular el cual persiste en la infancia y se ha asociado a enfermedades cardiovasculares en el adulto. La hipertensión en la infancia se ha demostrado como un factor de riesgo cardiovascular para la enfermedad adulta. Un seguimiento estricto junto con intervenciones en la dieta se ha demostrado mejora la salud cardiovascular en estos niños, sin embargo no todas las restricciones del crecimiento tienen hipertensión en la infancia. El objetivo principal de esta tesis es definir los parámetros con mayor utilidad de la ecocardiografía fetal para predecir hipertensión y remodelamiento arterial en infantes de 6 meses de edad con restricción del crecimiento intrauterino. Para esto, se realizó un estudio de cohorte incluyendo fetos con RCIU y controles, seguidos desde vida prenatal hasta los 6 meses de edad. La evaluación prenatal consistió en una ecocardiografía funcional completa. A los 6 meses de edad estos niños fueron evaluados para hipertensión y remodelamiento arterial. Posteriormente se realizó la construcción de un score cardiovascular para determinar desde vida prenatal aquellos niños con mayor riesgo a presentar hipertensión en vida postnatal y que pudieran requerir vigilancia o intervenciones.
APA, Harvard, Vancouver, ISO, and other styles
4

Berry, Karen L. (Karen Louise) 1972. "The structural basis of arterial stiffness and its relationship to cardiovascular outcome." Monash University, Dept. of Medicine, 2003. http://arrow.monash.edu.au/hdl/1959.1/7919.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Foley, Paul William Xavier. "Cardiovascular magnetic resonance in the prediction of outcome after cardiac resynchronisation therapy." Thesis, University of Birmingham, 2011. http://etheses.bham.ac.uk//id/eprint/2852/.

Full text
Abstract:
Contemporary management of patients with heart failure (HF) includes treatment with cardiac resynchronisation therapy (CRT). The benefit of CRT results from several mechanisms, predominantly correction of dyssynchrony. The development of a novel method of measuring left ventricular global dyssynchrony using cardiovascular magnetic resonance (CMR), termed CMR-tissue synchronisation index (CMR-TSI) is described. A study of 225 patients with HF who underwent CMR-TSI found that HF appears synonymous with dyssynchrony. The importance of myocardial scar is illustrated in a study of 95 patients which revealed a significantly higher mortality in patients undergoing CRT who had postero-lateral (PL) scar on CMR. A study into the effects of a combination of CMR-TSI and scar imaging found that presence of either CMR-TSI >110ms or PL scar resulted in a worse outcome, whilst the presence of both was associated with the highest mortality. A final study in 148 patients allowed the development of a risk score to predict mortality from CRT on the basis of 16 candidate variables. PL scar, dyssynchrony and creatine discriminated between survivors and non-survivors and were used to derive the score. The score is discussed in the context of data derived from echocardiography and clinical studies.
APA, Harvard, Vancouver, ISO, and other styles
6

Boyne, Pierce. "Aerobic Deconditioning after Stroke: Optimizing Outcome Measures and Interventions." University of Cincinnati / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1511867874726817.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Junttila, E. (Eija). "Cardiovascular abnormalities after non-traumatic intracranial hemorrhage." Doctoral thesis, Oulun yliopisto, 2012. http://urn.fi/urn:isbn:9789526200200.

Full text
Abstract:
Abstract Cardiovascular abnormalities are frequent after non-traumatic intracranial hemorrhage (NT-IH). They have mainly been studied in patients with subarachnoid hemorrhage (SAH), in which they have been reported to be associated with a poorer outcome. The aim of this observational clinical study was to evaluate cardiovascular abnormalities in patients with NT-IH requiring intensive care: clinical picture, predisposing factors and impact on outcome were examined. Additionally, the validity of cardiac output (CO) monitoring via uncalibrated arterial pressure waveform analysis (APCO, FloTrac/Vigileo™) was evaluated. The thesis was comprised of retrospective (n=229) and prospective (n=108) studies. The cardiovascular abnormalities evaluated were repolarization abnormalities (RAs) in electrocardiography (ECG), myocardial injury and dysfunction, and neurogenic pulmonary edema (NPE). Cardiovascular dysfunction severity was assessed using the Sequential Organ Failure Assessment cardiovascular (SOFAcv) score. Predisposing factors for RAs and NPE were examined. The one-year mortality and functional outcome were assessed. APCO was compared with the intermittent bolus thermodilution technique (TDCO). Cardiovascular abnormalities were almost universal after NT-IH and comparable after intracerebral hemorrhage (ICH) and SAH. Each RAs (QT interval prolongation, ischemic-like ECG changes and morphological end-repolarization abnormalities) had characteristic predisposing factors. The Acute Physiology And Chronic Health Evaluation (APACHE) II score ≥20 and systemic interleukin 6 concentration >40 pg/mL were independent predictors for NPE. In the retrospective study the mortality rate was 32% after SAH and 44% after ICH. In the prospective study the rates for mortality were 18% vs. 29% and for a poor functional outcome 41% vs. 69%, respectively. Ischemic-like ECG changes were associated with a poorer functional outcome. APCO underestimated CO compared to TDCO and was biased by low systemic vascular resistance (SVR). In conclusion, cardiovascular abnormalities after NT-IH are comparable after SAH and ICH. Predisposing factors for each RAs vary. Inflammatory mechanisms play an important role in NPE development. Ischemic-like ECG changes are associated with a poorer one-year functional outcome. The validity of APCO is insufficient and biased by low SVR in patients with NT-IH
Tiivistelmä Sydämen ja verenkierron toimintahäiriöt ovat yleisiä ei-traumaattisen aivoverenvuodon (NT-IH) jälkeen. Niitä on tutkittu lähinnä lukinkalvonalaisvuotopotilailla (SAV), joilla niiden on todettu olevan yhteydessä huonompaan ennusteeseen. Tässä havainnoivassa kliinisessä tutkimuksessa selvitettiin tehohoidettujen NT-IH -potilaiden sydämen ja verenkierron toimintahäiriöiden kliinistä oirekuvaa, altistavia tekijöitä ja vaikutusta ennusteeseen. Tutkimuksessa arvioitiin myös valtimopainekäyräanalyysiin perustuvan monitorointimenetelmän (APCO, FloTrac/Vigileo™) luotettavuutta mitattaessa sydämen minuuttitilavuutta. Väitöskirjatyö koostui retrospektiivisesta (n=229) ja prospektiivisesta (n=108) tutkimuksesta. Tutkittavia toimintahäiriöitä olivat elektrokardiografiassa (EKG) nähtävät repolarisaatiohäiriöt (RAs), sydänlihaksen vaurio ja supistumishäiriö sekä keuhkopöhö. Sydämen ja verenkierron toimintahäiriön yleistä vaikeusastetta arvioitiin SOFAcv -pisteytyksellä. RAs:lle ja keuhkopöhölle altistavia tekijöitä määritettiin. Potilaiden kuolleisuus ja toiminnallinen ennuste selvitettiin vuoden seuranta-aikana. APCO:a verrattiin lämpölaimennusmenetelmään (TDCO). Sydämen ja verenkierron toimintahäiriöitä esiintyi lähes kaikilla, eivätkä ne oirekuvaltaan eronneet aivokudoksen sisäistä vuotoa (ICH) ja SAV:a sairastavilla potilailla. Eri RAs:llä (QT-ajan pidentyminen, iskeemistyyppiset EKG-muutokset ja loppurepolarisaation morfologiset poikkeavuudet) oli kullekin ominaiset altistavat tekijät. APACHE II –pisteet ≥20 ja veren interleukiini 6 –pitoisuus >40 pg/ml ennustivat keuhkopöhön kehittymistä. Retrospektiivisessä aineistossa kuolleisuus oli 32 % SAV-potilailla ja 44 % ICH-potilailla. Prospektiivisessa aineistossa kuolleisuus ja huono toiminnallinen ennuste olivat vastaavasti 18 % vs. 29 % ja 41 % vs. 69 %. Iskeemistyypiset EKG-muutokset olivat yhteydessä huonompaan toiminnalliseen ennusteeseen. APCO aliarvioi TDCO:a matalan systeemiverenkierron vastuksen (SVR) kasvattaessa harhaa. Yhteenvetona todettakoon, että sydämen ja verenkierron toimintahäiriöt eivät eroa SAV- ja ICH-potilailla. Eri RAs:lle altistavat kullekin ominaiset tekijät. Tulehdukselliset mekanismit ovat keskeisiä keuhkopöhön kehittymisessä. Iskeemistyyppiset EKG-muutokset ovat yhteydessä huonompaan toiminnalliseen ennusteeseen. APCO:n luotettavuus NT-IH -potilailla on riittämätön, ja harhaa lisää matala SVR
APA, Harvard, Vancouver, ISO, and other styles
8

Marks, Edward Charles Arthur. "Potential use of sFlt-1 and pterin to predict the clinical outcome of cardiovascular disease." Thesis, University of Canterbury. Biological sciences, 2015. http://hdl.handle.net/10092/10851.

Full text
Abstract:
Formation of functional collateral circulation, to repair blocked or damaged arterial blood flow, is an important process in amending adverse outcomes after acute coronary occlusion events. Inadequate capillary growth during pressure overloads impairs myocardial perfusion, often contributing to the progression of coronary heart disease and ischaemia. Considered to be the critical rate-limiting step in physiological angiogenesis, the binding of VEGF (vascular endothelial growth factor) to VEGFR (vascular endothelial growth factor receptors) is essential for the growth and repair of arteries. Conversely, VEGF mediated angiogenesis has also been shown to promote atherosclerosis through arterial wall thickening. However, an alternatively spliced soluble form of VEGFR-1 (sFlt-1) has been shown to inhibit VEGF activity. sFlt-1 binds and sequesters free extracellular VEGF and/or heterodimerizes with VEGFR preventing the angiogenic pathway occurring. As a result, the primary pathway of angiogenesis does not occur. In recent years this has led to debate over the nature of sFlt-1 in the VEGF system. However, the level of sFlt-1 found in cardiovascular disease (CVD) patients, as well as its stability in plasma, has allowed for current research into its involvement with ischemic disorders to take place. Enhanced T-cell activity that results in increased production of interferon-γ has been shown to have involvement in the pathogenesis of CVD. 7,8-dihydroneopterin (7,8 NP) production by monocytes and macrophages is primarily in response to stimulation by interferon-γ (IFN-γ) released by activated T-lymphocytes. When combined with neopterin, the oxidised product of 7,8 NP, the total neopterin is accounted for which is a measure of the total macrophage activation by interferon-γ. Therefore, the levels of total neopterin observed may reflect the level of cell-mediated immunity within individuals which could contribute to mortality post CVD event. Progression of coronary heart disease is often clinically silent, without signs or symptoms. For this reason, the ability of markers to monitor progression is a powerful tool for predicting cardiovascular risk and the level of preventative treatment required. This study shows, that in 514 stable post-ACS (MI or unstable angina) patients, above median baseline sFlt-1, total neopterin and 7,8 NP levels, were strong predictors of mortality over a median 5 year period. Furthermore, above median sFlt-1 levels were specifically predictive of CVD death (p=0.001). This suggests that sFlt-1, total neopterin and 7,8 NP may be useful markers for risk prediction in CVD patients, post-acute event, with potential to aid prognosis in previously diagnosed patients. In support of these findings, levels of sFlt-1 measured in plasma taken from patients, immediately prior to undergoing carotid endarterectomy procedures (n=27), were significantly raised in comparison to age and gender matched healthy controls (p<0.001). Furthermore, levels of sFlt-1 in patient and control groups were shown to be independent of both age and gender. Another aspect of the study, analysis of excised live plaque tissue from carotid endarterectomy patients, showed the presence of live inflammatory cell populations. Macrophages, in the plaque sections, could be stimulated in the presence of IFN-γ to produce significantly elevated (p<0.01) levels of the antioxidant 7,8 NP. Since bivariate analysis of 7,8 NP and sFlt-1, in plasma from the endarterectomy patients, yields a positive correlation (r=0.323, p<0.01), further analysis of live plaque may give insight into the association between inflammation and hypoxic up-regulation of sFlt-1. It is now generally accepted, in diseases with complex pathogenesis, that particular biomarkers are predominantly indicative of only a single variable in a wide range of contributing factors. The data generated in this study highlights the potential for sFlt-1, neopterin and 7,8 NP to be used as contributing biomarkers in the prognosis of patients suffering from CVD, which if confirmed, may have important clinical implications in the medical community.
APA, Harvard, Vancouver, ISO, and other styles
9

George, Anish. "Prevalence of glucometabolic disorders in acute coronary syndrome and their prognostic influence in long term cardiovascular outcome." Thesis, University of Hull, 2016. http://hydra.hull.ac.uk/resources/hull:14392.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zen, Monica. "Pre-Eclampsia: Prediction, Prevention And Long-Term Sequelae." Thesis, The University of Sydney, 2022. https://hdl.handle.net/2123/29566.

Full text
Abstract:
Preeclampsia is a multi-system disorder that affects approximately 3-5% of all pregnancies and is one of the leading causes of maternal and neonatal morbidity and mortality globally. At present, there remain many facets of preeclampsia lacking data and comprehensive understanding. This thesis presents a number of studies investigating various aspects of prediction, prevention and long-term sequelae of preeclampsia. Women with pre-existing diabetes mellitus (DM) form a unique cohort of women with significantly increased risk of developing preeclampsia in pregnancy compared to the general population. Despite this, there is minimal data on serum predictive markers and no data on urinary predictive markers for the development of preeclampsia in this cohort. This thesis explored both urinary and serum predictive markers for preeclampsia throughout pregnancy, in women with pre-existing DM. We described urinary protein excretion as pregnancy progresses in women with pre-existing DM. For total protein excretion measured via spot urine protein-to-creatinine ratio (uPCR), results were in keeping with the literature within the general obstetric population, with increments as pregnancy progressed. However, unlike the general population, in our population of women with pre-existing DM, spot urinary albumin-to-creatinine ratio (uACR) remained stable until late trimester 3. We additionally found that for our population, in each trimester of pregnancy, spot uACR outperformed spot uPCR with respect to its association with the outcome of preeclampsia. Additionally, placental growth factor (PlGF) is known to play a key role in placental angiogenesis in pregnancy - we found that preeclampsia is associated with an anti-angiogenic state, with reduced levels of serum PlGF and increased levels of soluble fms-like protein kinase 1 (sFlt1). We demonstrated correlation between urinary and serum levels of PlGF throughout pregnancy and in contrast to the literature within the general obstetric population, we found that for our women with DM, serum PlGF alone performed as a better predictor of preeclampsia than the serum sFlt1-to-PlGF ratio, at all gestations sampled throughout pregnancy. Due to their increased preeclampsia risk, there is clear consensus that women with pre-existing DM would benefit from aspirin prophylaxis for preeclampsia risk reduction. These recommendations appear to stem from data obtained in the general population. However, there is evidence suggesting potentially reduced aspirin effectiveness in those with pre-existing DM. We reviewed the current literature of preeclampsia risk reduction with aspirin prophylaxis within women with pre-existing DM. Our systematic review is the first published review exploring the available data around the use of antenatal aspirin for the prevention of preeclampsia specifically in women with pre-existing DM. Our findings revealed a great void of available data surrounding aspirin prophylaxis for preeclampsia risk reduction in this cohort, with results suggesting no difference in preeclampsia outcome with aspirin use, a finding likely a consequence of lack of power due to insufficient data available for our cohort of interest. Preeclampsia not only poses immediate risk to the mother and neonate during the peripartum period, but it is now understood that it has long-term implications for both the mother and offspring. A wealth of evidence now exists demonstrating women with a history of preeclampsia have increased long term risk of cardiovascular morbidity and mortality. It appears that preeclampsia history may be a gender specific cardiovascular risk factor akin to traditional cardiovascular risk factors such as hypertension or obesity. It is known that those with increased cardiovascular risk are also at increased cardiovascular morbidity and mortality post-surgery. However, no data exists regarding postoperative cardiovascular risk in women with a history of preeclampsia. We aimed to explore this association in the PREECLAMPSIA-VISION study, a sub-study including all female participants with a positive pregnancy history from the original Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION) study, a large international prospective cohort study of a representative sample of adults aged 45 years and older who underwent non-cardiac surgery. Our primary outcome was Myocardial Injury after Non-cardiac Surgery (MINS) within 30 days after surgery. We found that a positive preeclampsia history was an independent risk factor for MINS, with 26% relative increase in the hazard of MINS in the first 30 post-operative days when compared to women whose previous pregnancies were not complicated by preeclampsia. In addition to long-term implications for the woman, epidemiological evidence also supports an association between maternal preeclampsia and long-term neurocognitive function in the offspring. However, the available literature is conflicting and there is often incomplete consideration of confounding factors. We explored this association, taking into account important confounding and mediating factors, via a population-based cohort study using record-linkage of New South Wales birth, hospitalization and education data. Our outcome of measure for neurocognitive function was offspring school performance as assessed by the Grade 3 National Assessment Program–Literacy and Numeracy (NAPLAN), a standardised national test, which assesses children in 5 domains: reading, writing, spelling, grammar and punctuation, and numeracy. Our outcome of interest was a score below the national minimal standard (BNMS) in any of the 5 NAPLAN domains. In children exposed to preeclampsia in utero, crude univariate analysis demonstrated an increased risk of scoring BNMS in all 5 NAPLAN domains compared to children of unaffected pregnancies. Interestingly, once perinatal and child factors were accounted for, these differences were completely attenuated. The perinatal factors had a greater mediating effect than child factors, with gestational age at birth being the primary contributor, accounting for up to 21% of the association between preeclampsia and scoring BNMS. All the studies presented within this thesis have either direct clinical implication or translational potential to clinical practice and have laid the foundation for further research. We suggest that women with pre-existing DM form a unique high-risk cohort of women with respect to the outcome of preeclampsia, and screening with uACR instead of the current clinically used uPCR would provide improved risk stratification for this cohort. Our results also suggest that the implementation of current clinically used algorithm-based screening, particularly those that include serum sFlt1-to-PlGF ratio may not be appropriate for women with pre-existing DM and screening within this cohort cannot be based on extrapolation of data obtained from the general obstetric population. Additionally, urinary PlGF holds promise for preeclampsia screening within this cohort and possibly the general obstetric population, however more sensitive commercially available kits are required. Further, we suggest caution before extrapolating currently available data for preeclampsia risk reduction with aspirin prophylaxis to women with pre-existing DM. Our PREECLAMPSIA-VISION study underscores the distinct requirement for enhancement in our overall understanding of gender differences in perioperative cardiovascular outcomes and overall long-term cardiovascular risk and suggests benefit in the incorporation of preeclampsia history into current perioperative risk predictive models for female patients. Lastly, to reduce the risk of poorer long-term offspring educational outcomes associated with preeclampsia, we support the implementation of strategies to safely prolong pregnancy and increase gestational age at birth in women whose pregnancies are complicated by preeclampsia.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cardiovascular outcome"

1

L, Flarey Dominick, and Blancett Suzanne Smith, eds. Cardiovascular outcomes: Collaborative, path-based approaches. Gaithersburg, Md: Aspen Publishers, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

O'Brien, Bernie. Measures of outcome in cardiovascular cost-benefit studies: A critical review. Uxbridge, Middx: Health Economics Research Group, Brunel University, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

P, Cannon Christopher, and O'Gara Patrick T, eds. Critical pathways in cardiovascular medicine. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

United States. Agency for Healthcare Research and Quality. and Southern California Evidence-Based Practice Center/RAND., eds. Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1947-, Morrison Douglass Andrew, and Serruys P. W, eds. High-risk cardiac revascularization and clinical trials. London: Martin Dunitz, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Simon, Stewart, and Blue Lynda, eds. Improving outcomes in chronic heart failure: Specialist nurse intervention from research to practice. 2nd ed. London: BMJ Books, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Athanasiou, Thanos, Ara Darzi, and Aung Ye Oo, eds. Patient Reported Outcomes and Quality of Life in Cardiovascular Interventions. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-09815-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

S, Coselli Joseph, and LeMaire Scott A, eds. Aortic arch surgery: Principles, strategies, and outcomes. Chichester, UK: Wiley-Blackwell, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Endothelial function and dysfunction: Improving cardiovascular patient care and outcomes in the twenty-first century. 2nd ed. Arvada, Co: 21st Century Press Books for Doctors, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Commission, Colorado Health Data, ed. Colorado hospital outcomes: Mortality, length of stay, and charges for cardiovascular and other diseases, 1992. Denver: Colorado Health Data Commission, Office of Public and Private Initiatives, Dept. of Health Care Policy & Financing, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cardiovascular outcome"

1

Shaper, A. G., S. G. Wannamethee, and M. K. Walker. "Risk Factors and Cardiovascular Outcome." In Epidemiology of Peripheral Vascular Disease, 127–40. London: Springer London, 1991. http://dx.doi.org/10.1007/978-1-4471-1889-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Miller, Leslie W. "Heart Transplantation: Indications, Outcome, and Long-Term Complications." In Cardiovascular Medicine, 1417–41. London: Springer London, 2007. http://dx.doi.org/10.1007/978-1-84628-715-2_67.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wilcken, David E. L., and Bridget Wilcken. "The Long-Term Outcome in Homocystinuria." In Developments in Cardiovascular Medicine, 51–56. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5771-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

AbuRahma, Ali F., and Patrick A. Stone. "Carotid Artery Stenting and Outcome Predictors." In Biomarkers in Cardiovascular Disease, 723–36. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-007-7678-4_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

AbuRahma, Ali F., and Patrick A. Stone. "Carotid Artery Stenting and Outcome Predictors." In Biomarkers in Cardiovascular Disease, 1–14. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7741-5_33-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Block, Michael, and Günther Breithardt. "Long-term outcome with transvenous (-subcutaneous) defibrillation leads." In Developments in Cardiovascular Medicine, 337–46. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0219-0_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kumar, Rekha B. "Cardiovascular Outcome Profiles of Anti-Diabetes Medications." In Obesity Management, 49–52. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-01039-3_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kaplan, Robert M. "Measures of Health Outcome in Social Support Research." In Social Support and Cardiovascular Disease, 65–94. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4899-2572-5_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mitchell, L. Brent. "Incidence, Timing and Outcome of Atrial Tachyarrhythmias After Cardiac Surgery." In Developments in Cardiovascular Medicine, 37–50. Boston, MA: Springer US, 2000. http://dx.doi.org/10.1007/978-0-585-28007-3_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Machado Reyes, Diego, Hanqing Chao, Fatemeh Homayounieh, Juergen Hahn, Mannudeep K. Kalra, and Pingkun Yan. "Cardiovascular Disease Risk Improves COVID-19 Patient Outcome Prediction." In Machine Learning in Medical Imaging, 467–76. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-87589-3_48.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cardiovascular outcome"

1

Plekhova, N. G., K. V. Grunberg, S. V. Dolzhikov, V. A. Nevzorova, and L. V. Rodionova. "Medical Instrument-Computer system for calculating the fatal outcome of cardiovascular diseases system for calculating the outcome of cardiovascular diseases." In 2017 Second Russia and Pacific Conference on Computer Technology and Applications (RPC). IEEE, 2017. http://dx.doi.org/10.1109/rpc.2017.8168085.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kelham, Matthew, Roy Wang, Artur Kowalczyk, Krishnaraj Rathod, Constantinos OMahony, Andrew Wragg, Andreas Baumbach, Anthony Mathur, and Dan Jones. "41 Public reporting of outcomes after percutaneous coronary intervention: is mortality the best outcome?" In British Cardiovascular Society Annual Conference, ‘100 years of Cardiology’, 6–8 June 2022. BMJ Publishing Group Ltd and British Cardiovascular Society, 2022. http://dx.doi.org/10.1136/heartjnl-2022-bcs.41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kelham, Matthew, Roy Wang, Artur Kowalczyk, Krishnaraj Rathod, Constantinos OMahony, Andrew Wragg, Andreas Baumbach, Anthony Mathur, and Dan Jones. "41 Public reporting of outcomes after percutaneous coronary intervention: is mortality the best outcome?" In British Cardiovascular Society Annual Conference, ‘100 years of Cardiology’, 6–8 June 2022. BMJ Publishing Group Ltd and British Cardiovascular Society, 2022. http://dx.doi.org/10.1136/heartjnl-2022-bcs.41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Brickwedel, J., T. J. Demal, L. Bax, H. Reichenspurner, and C. Detter. "Midterm Outcome after Frozen Elephant Trunk Procedures." In 49th Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1705317.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kalászi, Mariann, Renáta Laczik, Pál Soltész, Katalin Hodosi, Szilvia Szamosi, Zoltán Szekanecz, and Gabriella Szücs. "AB0689 EVALUATION OF CARDIOVASCULAR DETERMINANTS OF DISEASE OUTCOME IN SYSTEMIC SCLEROSIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.2454.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bradley, Joshua, J. Bradley, EB Schelbert, LJ Bonnett, GA Lewis, J. Lagan, C. Orsborne, et al. "31 Remote myocardial fibrosis predicts adverse outcome following myocardial infarction." In British Society of Cardiovascular Magnetic Resonance (BSCMR) Annual Congress 2022. BMJ Publishing Group Ltd and British Cardiovascular Society, 2023. http://dx.doi.org/10.1136/heartjnl-2022-bscmr.30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Aljassem, M., L. Khizaneishvili, M. Noutsias, B. Hofmann, G. Veres, and G. Szabó. "Impact of BMI on Postoperative Outcome after TAVI." In 50th Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1725830.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Demal, T. J., L. Bax, J. Brickwedel, B. Reiter, E. Girdauskas, L. Conradi, H. Reichenspurner, and C. Detter. "Risk Factors for Impaired Neurological Outcome in Aortic Surgery." In 49th Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1705514.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bordas-Martínez, Jaume, Ricard Gavaldà, Jessica Shull, √anesa Vicens-Zygmunt, Lurdes Planas-Cerezales, Guadalupe Bermudo-Peloche, Salud Santos, et al. "IPF cluster analysis highlights diagnostic delay and cardiovascular comorbidities association with outcome." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa3745.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Immohr, M. B., P. Akhyari, C. Boettger, A. Mehdiani, H. Aubin, R. Westenfeld, S. Erbel-Khurtsidze, et al. "Impact of Cytomegalovirus Mismatch on Outcome after Heart Transplantation." In 50th Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1725803.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cardiovascular outcome"

1

Gao, Hongwei, Tao Liu, Li Wang, and Qiuhe Ji. Comparative efficacy of new antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A network meta-analysis if cardiovascular and renal outcome trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0070.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Qiu, Mei, Liang-Liang Ding, and Hai-Rong Zhou. Meta-analyzing the factors affecting the efficacy of SGLT2is on heart failure events based on cardiovascular outcome trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0094.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ghosal, Samit, and Binayak Sinha. The cardiovascular benefits of GLP1-RA are directly related to their positive effect on glycaemic control: A meta-regression analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0071.

Full text
Abstract:
Review question / Objective: P (patient population) = Type 2 diabetes patients with high CV risk or established atherosclerotic cardiovascular disease; I (intervention) = Received drugs: GLP1-RA; C (control group) = Compared to a control group that received a placebo; O (outcome) = Outcomes of interest included primary CV outcomes (MACE, CV death, MI, and Stroke). Condition being studied: To explore whether the heterogeneity associated with the primary outcomes benefits can be attributed to the metabolic improvements associated with GLP1-RA. The plan is to use HBA1c, weight, and SBP reduction as moderators attempting to explain any variance between the true and observed effect size.
APA, Harvard, Vancouver, ISO, and other styles
4

Qi, Xue, Hechen Zhu, Ru Ya, and Hao Huang. Omega-3 polyunsaturated fatty acids supplements and cardiovascular disease outcome: A systematic review and meta-analysis on randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Qiu, Mei, Liang-Liang Ding, and Hai-Rong Zhou. Comprehensive analysis of the safety of three new drug classes for type 2 diabetes: a meta-analysis of cardiovascular outcome trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhuo, Chuanjun, Hongjun Tian, Lina Wang, Xiangyang Gao, Li Ding, and Ming Liu. Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2020. http://dx.doi.org/10.37766/inplasy2020.8.0122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Qiu, Mei, Liang-Liang Ding, Miao Zhang, and Hai-Rong Zhou. Comparison of the cardiorenal benefits from SGLT2 inhibitors for patients with different underlying disease: a meta-analysis of cardiovascular and renal outcome trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2020. http://dx.doi.org/10.37766/inplasy2020.9.0091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Mingzhu, Wujisiguleng Bao, Luying Sun, Zhi Yao, and Xiyao Li. Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: meta-analysis of randomized clinical trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0020.

Full text
Abstract:
Review question / Objective: To assess the beneficial effect and safety of finerenone for patients with chronic kidney disease associated with type 2 diabetes. Condition being studied: Chronic kidney disease (CKD) is a major contributor to morbidity and mortality from non-communicable diseases, affecting almost 700 million people worldwide. Approximately 40% of patients with diabetes have CKD, which exposes them to a 3-fold higher risk of cardiovascular death versus those with T2D alone. Strategies to protect the kidneys of patients with CKD and T2D may reduce their risk of cardiovascular events. Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced composite kidney and cardiovascular outcome in trials involving patients with chronic kidney disease. Recently, quite a few clinical studies have been conducted to compare finerenone and placebo. Our meta-analysis aimed to investigate the efficacy and safety of finerenone in chronic kidney disease associated with T2D. 1st author* - Mingzhu Zhang and Wujisiguleng Bao contributed equally to this study.
APA, Harvard, Vancouver, ISO, and other styles
9

Li, Peng, Na jia, Bing Liu, and Qing He. Effect of cardiac shock wave therapy on adverse cardiovascular event for patients with coronary artery disease: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0103.

Full text
Abstract:
Review question / Objective: We have previously demonstrated that cardiac shock wave therapy (CSWT) effectively improves myocardial perfusion in patients with coronary artery disease (CAD). In this study, we want to address whether CSWT could decrease the risk of adverse cardiovascular events in CAD patients unsuitable for revascularization. Eligibility criteria: Trials are considered eligible if they meet these criteria: (1) patients included are diagnosed as refractory angina or ischemic heart failure; (2) the study i a randomized controlled trial (RCT) or a prospective cohort study; (3) intervention consisted of CSWT; (4) patients in the control group are treated with optimal medical therapy, (5)the primary outcome of interest Is rate of MACE. Exclusion criteria were (1) patients with acute myocardial infarction, (2) repeated CSWT, (3) with coronary artery revascularization, (4) without primary outcome, (5) retrospective study, and (6)duplicated data.
APA, Harvard, Vancouver, ISO, and other styles
10

Ding, Liang-Liang, Mei Qiu, and Yingxi Tang. Comparative efficacy of GLP-1 RAs and SGLT2 inhibitors for prevention of cardiorenal events in type 2 diabetes: a network meta-analysis of cardiovascular outcome trails. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cardiovascular outcome' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography